<DOC>
	<DOCNO>NCT02333565</DOCNO>
	<brief_summary>To determine combination everolimus octreotide exert anti-tumoral activity recurrent and/or aggressive meningioma growth limit adverse effect .</brief_summary>
	<brief_title>Combination Everolimus Octreotide LAR Aggressive Recurrent Meningiomas</brief_title>
	<detailed_description />
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Male Female patient ≥ 18 year old maximum limited age Histologically proven meningioma grade II III ; grade I meningioma may also include , progression document ( see criterion 3 ) , particularly case skull base location Progression define 2 different MRI increase meningioma 's surface ≥ 5 % 3 month period ( i.e . increase 5 % 3 month , 10 % 6 month , 15 % 9 months… ) apparition new unequivocal neurological symptom relate meningioma . We consider new unequivocal neurological symptom new occur neurological symptom , instance , hemiparesia , oculomotor nerve palsy , visual loss , facial nerve palsy , facial neuralgia , directly relate meningioma suggest meningioma growth increase meningioma compression neurological structure despite increase size MRIs . Patients must fail surgery , amenable new curative intend surgery Patients must fail radiotherapy and/or radiosurgery Prior chemotherapy allow , progression cytotoxic agent clearly document . An interval 4 week last administration cytotoxic agent warrant . Number prior chemotherapy limit . Patients give write consent Patients affiliate social insurance regime Adequate bone marrow function show : Absolute Neutrophil Count ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hb &gt; 9 g/dL Adequate liver function show ; serum bilirubin ≤ 1.5 x Upper Limit Normal ; International Normalized Ratio &lt; 1.3 ; alanine aminotransferase aspartate aminotransferase ≤ 2.5 x Upper Limit Normal Adequate renal function : serum creatinine ≤ 1.5 x Upper Limit Normal Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L fast triglyceride ≤ 2.5 x Upper Limit Normal . NOTE : In case one threshold exceed , patient include dyslipidemia treatment initiation . Patients symptomatic lithiasis Contra indication octreotide everolimus Women childbearing age use effective mean contraception Pregnant breastfeed woman adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout trial sex Patients receive investigational agent receive investigative drug therapy within last 30 day . Known intolerance hypersensitivity octreotide , everolimus rapamycin ( sirolimus , temsirolimus ) Uncontrolled diabetes mellitus define HbA1c &gt; 8.5 % Patients severe and/or uncontrolled medical condition : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤ 6 month prior inclusion , serious uncontrolled cardiac arrhythmia , active uncontrolled severe infection , cirrhosis , chronic active hepatitis chronic persistent hepatitis , severely impaired lung function ( spirometry Diffusing Capacity lung carbon monoxide 50 % less normal O2 saturation 88 % less rest room air ) , active , bleeding diathesis Patients receive chronic treatment immunosuppressive agent Patients know history HIV seropositivity Patients history another primary malignancy ≤ 3 year , exception nonmelanoma skin cancer , carcinoma situ uterine cervix . Females patient pregnant lactating , childbearing potential practicing medically acceptable method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>